Meeting
2024 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer.
Authors
Alexander E. Drilon
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
Alexander E. Drilon , Shivaani Kummar , Jessica Jiyeong Lin , Daniel Shao-Weng Tan , Victor Moreno , Serge Leyvraz , Biswajit Dubashi , Haresh KP , Domnita-Ileana Burcoveanu , Natascha Neu , Chiara E. Mussi , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02122913, NCT02576431
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8570)
DOI
10.1200/JCO.2024.42.16_suppl.8570
Abstract #
8570
Poster Bd #
434
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
First Author: Jessica Jiyeong Lin
Poster
2023 ASCO Annual Meeting
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: David S. Hong
Poster
2022 ASCO Annual Meeting
Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
First Author: Alexander E. Drilon
Poster
2022 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: Alexander E. Drilon